Humanigen Inc (fka HGENQ)

[TheGreatSwami]

Press Release:
* First ever demonstration that the spectrum of toxicities seen in CAR-T clinical trials can be effectively prevented in vivo

* Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization

* Lenzilumab (an anti-GM-CSF monoclonal antibody) used in combination with CAR-T therapy prevents the onset of cytokine release syndrome and significantly reduces neuroinflammation may prevent impairment of the blood-brain barrier and significantly reduce the neuroinflammation caused by CAR-T

* GM-CSF neutralization with lenzilumab is a next generation strategy to improve efficacy, safety and durability of CAR-T therapy


https://www.humanigen.com/press/Humanigen-Study-of-GM-CSF-Neutralization-with-CAR-T-Therapy-Accepted-as-Oral-Presentation-at-the-2019-Transplantation-%26-Cellular-Therapy-(TCT)-Annual-Meeting